The European Central Bank announced plans to initiate its stimulus plan on Monday which lifted the markets to a higher close with the Dow rising 38 points to 18,135. Nasdaq gained 15 points to 4,982.

On the upside

Golar LNG (Nasdaq: GLNG) entered a Memorandum of Understanding with Rosneft Oil for cooperation in the area of floating liquefaction and transportation of natural gas.

Canadian Solar (Nasdaq: CSIQ) reported sharply higher fourth quarter earnings and revenue.

PowerSecure International (NYSE: POWR) swung to a profit for the fourth quarter.

On the downside

Semtech (Nasdaq: SMTC) fell to a loss for the fourth quarter.

First quarter earnings and revenue slipped for Greif (NYSE: GEF) to fall short of analyst expectations.

Rite Aid (NYSE: RAD) reported a same store sales increase of 3.3% for the month of February but the pace slowed from January's 4.8% growth.

In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 4 on the NYSE and by more than 9 to 7 on Nasdaq. The broader S&P 500 rose 2 points to 2101. Bitcoin added $6 to $276.
The markets traded higher during the midday with the Dow rising 34 points to 18,131 after the European Central Bank lifted its eurozone growth forecast from 1% to 1.5%. Nasdaq added 12 points to 4,979.

On the upside

The Food and Drug Administration released briefing documents for Kythera Biopharma's (Nasdaq: KYTH) ATX-101 indicating a favorable benefit-risk assessment.

Vivint Solar (NYSE: VSLR) reported a smaller than expected loss for the fourth quarter.

Geron (Nasdaq: GERN) narrowed losses for the fourth quarter.

On the downside

Capnia (Nasdaq: CAPN) closed a transaction for Series B warrant holders to exercise their warrants and issued new Series C warrants.

Eclipse Resources (NYSE: ECR) widened losses for the fourth quarter.

Momo (Nasdaq: MOMO) widened fourth quarter losses.

In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 4 on the NYSE and by more than 3 to 2 on Nasdaq. The broader S&P 500 added a point to 2099. Bitcoin slipped $5 to $264.
Investors welcomed the European Central Bank's plan to begin buying government bonds on March 9. The markets opened higher with the Dow gaining 44 points to 18,141 and Nasdaq climbing 21 points to 4,988.

On the upside

Second Sight Medical Products (Nasdaq: EYES) announced the first successful implants of their Argus II Retinal Prosthesis System at two centers in Italy.

AbbVie (NYSE: ABBV) will pay a premium of approximately $21 billion to purchase Pharmacyclics (Nasdaq: PCYC).

Pacific Ethanol (Nasdaq: PEIX) reported higher fourth quarter earnings as revenue rose.

On the downside

Achillion Pharmaceuticals (Nasdaq: ACHN) widened losses for the fourth quarter.

Embraer (NYSE: ERJ) disappointed with sharply lower fourth quarter earnings as revenue fell.

Darling Ingredients (NYSE: DAR) reported sharply higher fourth quarter earnings and revenue but the stock price dropped.

In the broad market, declining issues outpaced advancers by a margin of more than 10 to 9 on both the NYSE and on Nasdaq. The broader S&P 500 added 4 points to 2103. Bitcoin slipped $1 to $268.
Disappointing jobs data weighed the markets down to a sharply lower close with the Dow plunging 106 points to 18,096. Nasdaq fell 12 points to 4,967.

On the upside

Career Education (Nasdaq: CECO) narrowed fourth quarter losses more than expected.

Shares of Capnia (Nasdaq: CAPN) continued rising.

Orexigen Therapeutics (Nasdaq: OREX) stock extended its gains.

On the downside

Quicksilver (NYSE: ZQK) delayed the release of its first quarter financials.

Profit taking weighed down shares of StemCells (Nasdaq: STEM).

Xplore Technologies (Nasdaq: XPLR) priced its offering of 2 million shares of common stock at the discounted price of $6 per share.

In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 3 on the NYSE and by more than 7 to 5 on Nasdaq. The broader S&P 500 lost 9 points to 2098. Bitcoin fell $11 to $268.
The markets traded lower during the midday with the Dow tumbling 99 points to 18,104 as oil prices fell and jobs data disappointed. Nasdaq lost 13 points to 4,966.

On the upside

Coronado Biosciences (Nasdaq: CNDO) formed a new subsidiary, Checkpoint Therapeutics, to develop immuno-oncology antibodies.

Wayfair (NYSE: W) widened losses for the fourth quarter but the results were better than expected.

Autohome (NYSE: ATHM) impressed with fourth quarter earnings that more than doubled as revenue surged.

On the downside

Fourth quarter earnings and revenue fell for Abercrombie & Fitch (NYSE: ANF).

Cyclacel Pharmaceuticals (Nasdaq: CYCC) priced its public offering of 10 million common shares at the discounted price of $1.00 per share.

TriNet Group (NYSE: TNET) reported higher fourth quarter earnings and revenue but the stock price fell after Deutsche Bank cut its price target on the company from $40 to $35.

In the broad market, declining issues outpaced advancers by a margin of nearly 7 to 2 on the NYSE and by nearly 5 to 2 on Nasdaq. The broader S&P 500 lost 9 points to 2098. Bitcoin held steady at $279.
The nation's private employers added fewer than expected jobs in February sending the markets tumbling to a sharply lower open with the Dow plunging 156 points to 18,046. Nasdaq dropped 35 points to 4,944.

On the upside

Novogen (Nasdaq: NVGN) announced that TRXE-009 demonstrated potential to kill brain cancer stem cells.

InfoSonics (Nasdaq: IFON) reported sharply higher fourth quarter earnings as revenue soared.

Third quarter earnings and revenue dropped for Smith & Wesson (Nasdaq: SWHC) but the results were better than expected.

On the downside

Veeva Systems (NYSE: VEEV) reported higher fourth quarter earnings and revenue but the stock price fell when the company announced plans to acquire Qforma CrowdLink for an undisclosed amount.

Bazaarvoice (Nasdaq: BV) reported a loss for the third quarter.

Bob Evans Farms (Nasdaq: BOBE) reported lower third quarter earnings even as revenue rose.

In the broad market, declining issues outpaced advancers by a margin of nearly 7 to 2 on the NYSE and by more than 5 to 2 on Nasdaq. The broader S&P 500 tumbled 18 points to 2088. Bitcoin added $1 to $280.
The markets closed lower with the Dow tumbling 85 points to 18,203 as February auto sales disappointed. Nasdaq fell 28 points to 4,979.

On the upside

Intrexon (NYSE: XON) reversed year ago losses to post a profit for the fourth quarter as revenue quadrupled.

MarketWatch listed Capnia (Nasdaq: CAPN) as one of the most profitable Nasdaq biotech companies.

DTS (Nasdaq: DTSI) reported sharply lower fourth quarter earnings but the results were better than expected.

On the downside

Primoris Services (Nasdaq: PRIM) disappointed with sharply lower fourth quarter earnings that fell far short of analyst expectations.

NorthStar Realty Finance (NYSE: NRF) priced its public offering of 60 million common shares at the discounted price of $18.65 per share.

Nomura downgraded Micron Technology (Nasdaq: MU) from a Buy rating to a Neutral rating.

In the broad market, declining issues outpaced advancers by a margin of more than 7 to 5 on the NYSE and by nearly 2 to 1 on Nasdaq. The broader S&P 500 lost 9 points to 2107. Bitcoin gained $9 to $278.
Disappointing February auto sales sent the markets tumbling during the midday with the Dow plunging 108 points to 18,180. Nasdaq dropped 39 points to 4,968.

On the upside

Orexigen Therapeutics' (Nasdaq: OREX) obesity treatment Contrave reduced the risk of heart disease by almost half.

Nutrisystem (Nasdaq: NTRI) reported sharply higher fourth quarter earnings that topped analyst estimates.

Janney Capital Markets analyst David Strasser upgraded Lumber Liquidators Holdings (NYSE: LL) from a Neutral rating to a Buy rating and affirmed his $47 price target.

On the downside

Opower (NYSE: OPWR) widened losses for the fourth quarter.

SunOpta (Nasdaq: STKL) widened fourth quarter losses more than expected.

Akorn (Nasdaq: AKRX) filed for an extension for its Form 10-K.

In the broad market, declining issues outpaced advancers by a margin of more than 5 to 3 on the NYSE and by more nearly 2 to 1 on Nasdaq. The broader S&P 500 dropped 13 points to 2103. Bitcoin added $4 to $273.

Lower open as oil prices slide

|
Retreating crude oil prices weighed the markets down to a lower open with the Dow dropping 70 points to 18,218. Nasdaq fell 24 points to 4,983.

On the upside

The Food and Drug Administration granted Orphan Drug Designation to Oncolytics Biotech's (Nasdaq: ONCY) primary peritoneal cancer treatment Reolysin.

McDermott International (NYSE: MDR) reversed year ago losses to post an unexpected profit for the fourth quarter as revenue soared.

Springleaf Holdings (NYSE: LEAF) will pay approximately $4.25 billion in cash to acquire Citigroup's (NYSE: C) OneMain Financial Holdings consumer finance unit.

On the downside

Goldman Sachs downgraded MannKind (Nasdaq: MNKD) from a Neutral rating to a Sell rating and slashed its price target from $6 to $3.

Cumulus Media (Nasdaq: CMLS) disappointed with sharply lower fourth quarter earnings that fell short of expectations.

Arena Pharmaceuticals (Nasdaq: ARNA) widened losses for the fourth quarter.

In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 2 on the NYSE and by more than 5 to 2 on Nasdaq. The broader S&P 500 fell 9 points to 2107. Bitcoin lost $3 to $265.

Strong March open

|
The month of March began strong with the Dow jumping 155 points to 18,288. Nasdaq soared 44 points to close at 5,008, topping 5,000 for the first time in fifteen years.

On the upside

Tracon Pharmaceuticals (Nasdaq: TCON) reported positive results from a Phase 1b clinical trial of TRC105 with Inlyta(R) in patients with advanced or metastatic renal cell carcinoma.

Cisco Systems (Nasdaq: CSCO) introduced its Universal Small Cell (USC) 8000 Series for large enterprises.

Bargain hunters lifted shares of 500.com (NYSE: WBAI).

On the downside

Goodrich Petroleum (NYSE: GDP) will offer 12 million shares of common stock.

BioScrip (Nasdaq: BIOS) widened fourth quarter losses more than expected.

The Food and Drug Administration issued a Complete Response Letter to Pacira Pharmaceuticals (Nasdaq: PCRX) for its supplemental New Drug Application for the expanded use of Exparel.

In the broad market, advancing issues outpaced decliners by a margin of nearly 3 to 2 on the NYSE and by nearly 2 to 1 on Nasdaq. The broader S&P 500 climbed 12 points to 2117. Bitcoin climbed $16 to $271.

Monthly Archives

Powered by Movable Type 5.12